Lead and cadmium have stay of execution in EU
This article was originally published in Clinica
The European Commission has decided to allow lead and cadmium, frequently used in medical devices, including clinical analysers, to remain on the market for longer than originally anticipated in the context of its Directive on the restriction of the use of certain hazardous substances in electrical and electronic equipment (the RoHS Directive, 2002/95/EC).
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.